SHARON GIORDANI: Open Payments
NPI 1720201965 · QUINCY, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$522 in 28 payments from 11 companies in 2025. Trend: 2023 $322 · 2024 $472 · 2025 $522
Food & beverage: $522
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 10 | $153 |
| Novo Nordisk Inc | 4 | $75 |
| Organon LLC | 2 | $55 |
| UCB, Inc. | 2 | $49 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $39 |
| GlaxoSmithKline, LLC. | 2 | $34 |
| Currax Pharmaceuticals LLC | 2 | $32 |
| Janssen Biotech, Inc. | 1 | $30 |
| Lilly USA, LLC | 1 | $20 |
| ANI Pharmaceuticals, Inc. | 1 | $20 |
Products named: OTEZLA, HADLIMA, Wegovy, Bimzelx, XIFAXAN, BENLYSTA, CONTRAVE, TREMFYA.
Industry payments across MA — which companies pay providers there.
